This company has been marked as potentially delisted and may not be actively trading. Vermillion (VRML) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock VRML vs. CDIO, TRIB, BMRA, VRAX, AWH, TNFA, MYMD, NAVB, IDXX, and LNTHShould you be buying Vermillion stock or one of its competitors? The main competitors of Vermillion include Cardio Diagnostics (CDIO), Trinity Biotech (TRIB), Biomerica (BMRA), Virax Biolabs Group (VRAX), Aspira Women's Health (AWH), TNF Pharmaceuticals (TNFA), MyMD Pharmaceuticals (MYMD), Navidea Biopharmaceuticals (NAVB), IDEXX Laboratories (IDXX), and Lantheus (LNTH). These companies are all part of the "medical" sector. Vermillion vs. Cardio Diagnostics Trinity Biotech Biomerica Virax Biolabs Group Aspira Women's Health TNF Pharmaceuticals MyMD Pharmaceuticals Navidea Biopharmaceuticals IDEXX Laboratories Lantheus Cardio Diagnostics (NASDAQ:CDIO) and Vermillion (NASDAQ:VRML) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends, community ranking and institutional ownership. Is CDIO or VRML more profitable? Vermillion has a net margin of -307.31% compared to Cardio Diagnostics' net margin of -22,732.03%. Vermillion's return on equity of -155.25% beat Cardio Diagnostics' return on equity.Company Net Margins Return on Equity Return on Assets Cardio Diagnostics-22,732.03% -258.85% -191.20% Vermillion -307.31%-155.25%-103.47% Does the MarketBeat Community favor CDIO or VRML? Vermillion received 200 more outperform votes than Cardio Diagnostics when rated by MarketBeat users. However, 80.00% of users gave Cardio Diagnostics an outperform vote while only 66.67% of users gave Vermillion an outperform vote. CompanyUnderperformOutperformCardio DiagnosticsOutperform Votes480.00% Underperform Votes120.00% VermillionOutperform Votes20466.67% Underperform Votes10233.33% Which has preferable earnings and valuation, CDIO or VRML? Cardio Diagnostics has higher earnings, but lower revenue than Vermillion. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCardio Diagnostics$34.89K634.89-$8.38MN/AN/AVermillion$4.54M1.29-$15.24MN/AN/A Do insiders & institutionals believe in CDIO or VRML? 8.1% of Cardio Diagnostics shares are owned by institutional investors. Comparatively, 18.1% of Vermillion shares are owned by institutional investors. 22.3% of Cardio Diagnostics shares are owned by insiders. Comparatively, 4.4% of Vermillion shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the media refer more to CDIO or VRML? In the previous week, Cardio Diagnostics had 1 more articles in the media than Vermillion. MarketBeat recorded 1 mentions for Cardio Diagnostics and 0 mentions for Vermillion. Cardio Diagnostics' average media sentiment score of 1.89 beat Vermillion's score of 0.00 indicating that Cardio Diagnostics is being referred to more favorably in the media. Company Overall Sentiment Cardio Diagnostics Very Positive Vermillion Neutral Which has more risk and volatility, CDIO or VRML? Cardio Diagnostics has a beta of 3.73, meaning that its share price is 273% more volatile than the S&P 500. Comparatively, Vermillion has a beta of 3.47, meaning that its share price is 247% more volatile than the S&P 500. Do analysts recommend CDIO or VRML? Cardio Diagnostics presently has a consensus price target of $2.00, suggesting a potential upside of 370.81%. Given Cardio Diagnostics' stronger consensus rating and higher possible upside, analysts plainly believe Cardio Diagnostics is more favorable than Vermillion.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardio Diagnostics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Vermillion 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryCardio Diagnostics beats Vermillion on 10 of the 16 factors compared between the two stocks. Get Vermillion News Delivered to You Automatically Sign up to receive the latest news and ratings for VRML and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VRML vs. The Competition Export to ExcelMetricVermillionDiagnostic Substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.84M$2.35B$5.56B$7.83BDividend YieldN/A0.75%5.11%4.22%P/E Ratio-0.356.4322.4418.48Price / Sales1.2950.54393.95103.59Price / CashN/A15.7538.1834.62Price / Book0.673.646.774.25Net Income-$15.24M-$65.73M$3.22B$248.23M Vermillion Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VRMLVermillionN/A$0.06flatN/A-98.1%$5.84M$4.54M-0.3543Gap DownCDIOCardio Diagnostics2.5623 of 5 stars$0.45-6.9%$2.00+343.8%-38.0%$23.50M$34,890.000.001Gap UpTRIBTrinity Biotech1.5707 of 5 stars$0.76+7.3%N/A-57.0%$13.72M$59.13M-0.34480Analyst ForecastShort Interest ↓BMRABiomerica0.9338 of 5 stars$3.84-1.0%N/A-24.1%$9.78M$5.68M-11.2960VRAXVirax Biolabs Group2.379 of 5 stars$1.11+5.7%$3.00+170.3%+55.6%$3.59M$84,872.000.005Short Interest ↑AWHAspira Women's Health2.0401 of 5 stars$0.08-12.5%$5.50+6,607.3%-97.5%$2.44M$9.18M-0.07110High Trading VolumeTNFATNF PharmaceuticalsN/A$0.22+1.3%N/AN/A$2.26MN/A-0.026News CoverageHigh Trading VolumeMYMDMyMD PharmaceuticalsN/A$0.22+14.6%N/A-92.8%$521,000.00N/A0.006Positive NewsHigh Trading VolumeNAVBNavidea BiopharmaceuticalsN/A$0.00flatN/A-98.3%$20,000.00$8,126.000.0010IDXXIDEXX Laboratories3.9547 of 5 stars$433.99-0.8%$523.75+20.7%-12.2%$35.17B$3.90B40.6710,800Positive NewsLNTHLantheus3.9823 of 5 stars$102.70+0.9%$129.43+26.0%+56.8%$7.03B$1.53B17.09700Upcoming EarningsPositive News Related Companies and Tools Related Companies Cardio Diagnostics Competitors Trinity Biotech Competitors Biomerica Competitors Virax Biolabs Group Competitors Aspira Women's Health Competitors TNF Pharmaceuticals Competitors MyMD Pharmaceuticals Competitors Navidea Biopharmaceuticals Competitors IDEXX Laboratories Competitors Lantheus Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VRML) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vermillion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vermillion With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VRML Stock Free VRML Stock Alerts